Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression.

Roger Nelson RodriguesDavid Chen-LiJoshua D Di VincenzoAshwin JunejaBenjamin D PinderRoger S McIntyreJoshua D Rosenblat

Published in: Journal of psychopharmacology (Oxford, England) (2024)

This study contributes to the growing literature that ketamine efficacy is unlikely to be predicted by single genes, and a pleiotropic approach may likely be necessary for developing reliable predictors of clinical benefits.

Keyphrases

systematic review
pain management
randomized controlled trial
depressive symptoms
genome wide
tyrosine kinase
gene expression
dna methylation
transcription factor
genome wide analysis